Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
01 oct. 2021 08h01 HE
|
Replimune Group Inc
WOBURN, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
06 août 2021 08h00 HE
|
Replimune Group Inc
Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma,...
Replimune to Present at Two Upcoming Investor Conferences
02 août 2021 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune to Present at the William Blair Biotech Focus Conference 2021
07 juil. 2021 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
03 juin 2021 07h00 HE
|
Replimune Group Inc
High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data...
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
20 mai 2021 08h00 HE
|
Replimune Group Inc
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma ...
Replimune Appoints Tanya Lewis as Chief Development Operations Officer
10 mai 2021 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma
05 mai 2021 07h00 HE
|
Replimune Group Inc
WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune to Host Virtual Investor Event on June 3, 2021
28 avr. 2021 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today...
Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer
21 avr. 2021 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...